Literature DB >> 12352222

Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods.

Ronald K Linskens1, Rosalie C Mallant-Hent, Z M Anthonie Groothuismink, Liesbeth E Bakker-Jonges, Joop P van de Merwe, Herbert Hooijkaas, B Mary E von Blomberg, Stephan G M Meuwissen.   

Abstract

BACKGROUND: Accurate diagnosis of inflammatory bowel disease, in particular the differentiation between ulcerative colitis and Crohn's disease, is important for treatment and prognosis. Several serological markers have been used as non-invasive diagnostic tools in inflammatory bowel disease patients both to differentiate ulcerative colitis from Crohn's disease and to define patient subgroups. AIM: To evaluate the diagnostic accuracy of three serological tests in differentiating ulcerative colitis from Crohn's disease by single or combined use.
METHODS: Sera from 51 patients with clinically well-defined ulcerative colitis and 50 patients with clinically well-defined Crohn's disease were analysed. Detection assays for the presence of perinuclear anti-neutrophil cytoplasmatic antibodies (pANCA), antibodies against (ASCA) and serum agglutinating antibodies to anaerobic coccoid rods were studied. Sensitivity, specificity, predictive values and likelihood ratios of each of these serological tests were determined.
RESULTS: In supporting the diagnosis of ulcerative colitis, the sensitivity and specificity of the pANCA test were 63% and 86%, respectively. The ASCA test (immunoglobulin A or immunoglobulin G positive) for diagnosing Crohn's disease had a sensitivity of 72% and a specificity of 82%. The sensitivity of antibodies to anaerobic coccoid rods in diagnosing Crohn's disease was 52%, whereas specificity was 90%. A combination of pANCA-positive and ASCA-negative results in the case of ulcerative colitis showed a sensitivity and specificity of 51% and 94%, respectively. However, for ASCA-positive and pANCA-negative results in the case of Crohn's disease, sensitivity was 64% and specificity was 94%. The combination of all three tests increased positive predictive value and specificity to 100% for both ulcerative colitis and Crohn's disease. In Crohn's disease patients, positive pANCA was correlated with colonic involvement. No correlation was found between the presence of any of these antibodies and disease activity, duration and behaviour or medical treatment.
CONCLUSIONS: The value of these serological tests in differentiating ulcerative colitis from Crohn's disease is limited when used separately but, by combining two or more tests, the positive predictive value and specificity can be improved substantially. These tests might be of help in studying disease heterogeneity, and may contribute to defining various subgroups of patients with different pathogeneses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352222     DOI: 10.1097/00042737-200209000-00013

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  18 in total

1.  Anti-Saccaromyces Cerevisiae antibodies (ASCA) are elevated in autoimmune thyroid disease ASCA in autoimmune thyroid disease.

Authors:  Dilek Yazıcı; Sibel Zehra Aydın; Dilek Yavuz; Ozlem Tarçın; Oğuzhan Deyneli; Haner Direskeneli; Sema Akalın
Journal:  Endocrine       Date:  2010-07-16       Impact factor: 3.633

Review 2.  Relevance of serologic studies in inflammatory bowel disease.

Authors:  Gwenola Vernier; Boualem Sendid; Daniel Poulain; Jean-Frédéric Colombel
Journal:  Curr Gastroenterol Rep       Date:  2004-12

3.  The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn's disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway.

Authors:  S Ouburg; R Mallant-Hent; J B A Crusius; A A van Bodegraven; C J J Mulder; R Linskens; A S Peña; S A Morré
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 4.  Location is important: differentiation between ileal and colonic Crohn's disease.

Authors:  Raja Atreya; Britta Siegmund
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-03-12       Impact factor: 46.802

5.  Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.

Authors:  Troy D Jaskowski; Christine M Litwin; Harry R Hill
Journal:  Clin Vaccine Immunol       Date:  2006-06

6.  Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis.

Authors:  Vishal Anand; Anthony S Russell; Ross Tsuyuki; Richard Fedorak
Journal:  Can J Gastroenterol       Date:  2008-01       Impact factor: 3.522

7.  Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation.

Authors:  Anupa Kamat; Petronela Ancuta; Richard S Blumberg; Dana Gabuzda
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

8.  Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD.

Authors:  R-C Mallant-Hent; M Mooij; B-Me von Blomberg; R-K Linskens; A-A van Bodegraven; P-Hm Savelkoul
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

Review 9.  Utility of serological markers in inflammatory bowel diseases: gadget or magic?

Authors:  Maria Papp; Gary L Norman; Istvan Altorjay; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

10.  Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population.

Authors:  Muhammed Hadithi; Marcel Cazemier; Gerrit-A Meijer; Elisabeth Bloemena; Richel-J Felt-Bersma; Chris-J Mulder; Stephan-Gm Meuwissen; Amado-Salvador Pena; Adriaan-A van Bodegraven
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.